I-Mab (NASDAQ:IMAB) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• I-Mab has been downgraded from a "buy" rating to a "hold" rating by Wall Street Zen, reflecting a shift in analyst sentiment about the stock's prospects.
• Despite this downgrade, I-Mab retains a consensus "buy" rating among four analysts, with an average price target of $7.00.
• The company's recent earnings report indicated an EPS of ($0.07), which was better than analysts' expectations of ($0.10).

I-Mab (NASDAQ:IMAB - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Other equities research analysts have also issued reports about the stock. Loop Capital set a $8.00 target price on shares of I-Mab in a report on Thursday, August 28th. BTIG Research started coverage on shares of I-Mab in a research report on Tuesday, September 9th. They issued a "buy" rating and a $7.00 price objective on the stock. Brookline Capital Management reissued a "buy" rating on shares of I-Mab in a research report on Thursday, August 28th. Needham & Company LLC reissued a "buy" rating and issued a $6.00 price objective on shares of I-Mab in a research report on Monday, September 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of I-Mab in a research report on Thursday, August 21st. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $7.00.

I-Mab Stock Performance

Shares of IMAB stock opened at $3.79 on Friday. I-Mab has a one year low of $0.60 and a one year high of $5.90. The firm's 50 day moving average price is $3.57 and its 200-day moving average price is $2.10.

I-Mab (NASDAQ:IMAB - Get Free Report) last released its earnings results on Wednesday, August 20th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. On average, research analysts forecast that I-Mab will post -0.56 earnings per share for the current year.

Institutional Trading of I-Mab

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new stake in shares of I-Mab in the 4th quarter worth $93,000. Millennium Management LLC lifted its stake in shares of I-Mab by 763.1% in the 4th quarter. Millennium Management LLC now owns 97,749 shares of the company's stock worth $83,000 after acquiring an additional 86,424 shares during the period. HBK Sorce Advisory LLC acquired a new stake in shares of I-Mab in the 1st quarter worth $38,000. Ground Swell Capital LLC acquired a new stake in shares of I-Mab in the 1st quarter worth $53,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of I-Mab in the 1st quarter worth $398,000. Institutional investors and hedge funds own 38.38% of the company's stock.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.